Table 4.
Survival outcomes (months) in comparison with previous cohorts.
| CHT/RT (MMCI 2014–2017) n = 90 | CHT/RT (MMCI 2003–2009) n = 86 | CHT/RT [Stupp trial (1)] n = 287 | |
|---|---|---|---|
| Median follow up (months) | 34.8 | NA | 28 |
| Overall survival | |||
| Median | 16.0 | 13.8 | 14.6 |
| 1-year | 65% | 58% | 61% |
| 2-year | 31% | 28% | 27% |
| 3-year | 21% | 7% | 16% |
| 4-year | 10% | 2% | 12% |
| 5-year | NA | 2% | 10% |
| Progression free survival | |||
| Median | 6.7 | 7.8 | 6.9 |
| 1-year | 28% | 32% | 27% |
| 2-year | 14% | 9% | 11% |
OS, overall survival; PFS, progression free survival; CHT/RT, chemoradiotherapy; MMCI, Masaryk Memorial Cancer Institute; NA, Not Available.